Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Synthesis of peptides
Reexamination Certificate
2005-07-07
2009-10-13
Kosar, Andrew D (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Synthesis of peptides
C530S324000
Reexamination Certificate
active
07601802
ABSTRACT:
Cysteine containing amphipathic alpha helices of the exchangeable apolipoproteins, as exemplified by apolipoprotein (apo) A-IMilano(R173C) and apoA-IParis, (R151C) were found to exhibit potent antioxidant activity on phospholipid surfaces. The addition of a free thiol, at the hydrophobic/hydrophilic interface of an amphipathic alpha helix of synthetic peptides that mimic HDL-related proteins, imparts a unique antioxidant activity to these peptides which inhibits lipid peroxidation and protects phospholipids from water-soluble free radical initiators. These peptides can be used as therapeutic agents to combat cardiovascular disease, ischemia, bone disease and other inflammatory related diseases.
REFERENCES:
patent: 4643988 (1987-02-01), Segrest et al.
patent: 5721114 (1998-02-01), Abrahamsen et al.
patent: 5733549 (1998-03-01), Yamada et al.
patent: 5876968 (1999-03-01), Sirtori et al.
patent: 5955055 (1999-09-01), Lees et al.
patent: 6156727 (2000-12-01), Garber et al.
patent: 6258596 (2001-07-01), Benoit et al.
patent: 6596544 (2003-07-01), Fogelman et al.
patent: 6617156 (2003-09-01), Doucette-Stamm et al.
patent: 6635623 (2003-10-01), Hoogeveen et al.
patent: 6734169 (2004-05-01), Dasseux et al.
patent: 7217785 (2007-05-01), Bielicki
patent: 7223726 (2007-05-01), Oda et al.
Datta, et al.; “Aromatic Residue on the Nonpolar Face of Class A Amphipathic Helical Peptides Determines Biological Activity,”The Journal of Biological Chemistry; Jun. 18, 2004; pp. 26509-26517; vol. 279; No. 24; The American Society for Biochemistry and Molecular Biology, Inc.; USA.
Jia, et al.; “Thiol-bearing Synthetic Peptides Retain the Antioxidant Activity of ApolipoproteinA-I(Milano);”Biochemical and Biophysical Research Communications; Sep. 20, 2002; pp. 206-213; vol. 297; Issue 2; Elsevier Science.
Navab, et al.; “Thematic Review Series: The Pathogenesis of Atherosclerosis; The Oxidation Hypothesis of Atherogenesis: The Role of Oxidized Phosholipids and HDL;”;Journal of Lipid Research; Apr. 1, 2004; pp. 993-1007; vol. 45; The American Society for Biochemistry and Molecular Biology, Inc.
Reddy, et al. “ATP-Blnding Cassette Transporter 1 Participates in LDL Oxidation by Artery Wall Cells;”Arterioscler Thromb Vasc Biol.; Nov. 2002; pp. 1877-1883; vol. 22.
Schmitz, et al.; “ATP-Binding Cassette Transporter A1 (ABCA1) in Macrophages: A Dual Function in Inflammation and Lipid Metabolism?;”Pathobiology; 2000; pp. 238-240; vol. 67; Karger AG; Basel.
Sean Ameli et al., “Recombinant Apolipoprotein A-I Milano Reduces Intimal Thickening After Balloon Injury in Hypercholesterolemic Rabbits,” Circulation, 90, 4:1935-1941, (Oct. 13, 1994).
Gerd Assman et al., “High Density Lipoproteins, Reverse Transport of Cholesterol, and Coronary Artery Disease,” Circulation, vol. 87 ( No. 4), p. III-28-34, (Apr. 13, 1993).
John K. Bielicki et al., “Apolipoprotein A-IMilano and Apolipoprotein A-iParis Exhibit an Antioxidant Activity Distinct from That of Wild-type Apolipoprotein A-I,” Bichemistry, 41:2089-2096, (Jan. 2002).
Eric Bruckert et al, “The replacement of arginine by cysteine at residue 151 in Apolipoprotein A-I produces a phenotype similar to that of Apolipoprotein A-IMilano,” Atherosclerosis, 128:121-128, (1997).
Robert J. Brushia et al., “Baculovirus-mediated expression and purification of human serum paraoxonase 1A,” Journal of Lipid Research, 42: 951-958, (Jun. 2001).
Guido Franceschini et al., “A-IMilano Apoprotein: Decreased High Density Lipoprotein Cholesterol Levels with Significant Lipoprotein Modifications and Without Clinical Atherosclerosis in an Italian Family,” J. Clin. Invest., 66: 892-900, (Nov. 1980).
Guido Franceschini et al., “Apolipoprotein A-I Milano: Accelerated Binding and Dissociation From Lipids of a Human Apolipoprotein Variant,” J. Biol. Chem. 260, 30:16321-16325, (Dec. 1985).
David W. Garber et al., “A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis,” Journal of Lipid Research, 42: 545-552, (Apr. 2001).
Kristin L. Gillotte et al., “Apolipoprotein-mediated Plasma Membrane Microsolubilization,” Journal of Biological Chemistry, vol. 272 ( No. 4), p. 2021-2028, (Jan. 1999).
Armando J. Mendez et al., “Synthetic Amphipathic Helical Peptides That Mimic Apolipoprotein A-I in Clearing Cellular Cholesterol,” J. Clin. Invest., 94:1698-1705, (Oct. 1994).
Vinod K. Mishra et al., “Studies of Synthetic Peptides of Human Apoloprotein A-I Containing Tandem Amphipathic alpha-Helixes,” Biochemistry, 37: 10313-1032, ( Jun. 25, 1998).
Michael N. Oda et al., “Cysteine Substitutions in Apolipoprotein A-I Primary Structure Modulate Paraoxonase Activity,” Biochemistry, 40:1710-1718, ( Jan. 19, 2001).
Palgunachari et al., “Only the Two End Helixes of Eight Tandem Amphipathic Helical Domains of Human Apo A-I Have Significant Lipid Affinity,” Arteriosclerosis, Thrombosis, and Vascular Biology, 16, 2:328-338, ( Feb. 13, 1996).
Oscar Perez-Mendez et al., “Metabolism of Apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris,” Atherosclerosis, 148: 317-326, (2000).
Basil M. Rifkind, “High-Density Lipoprotein Cholesterol and Coronary Artery Disease:Survey of the Evidence,” The American Journal of Cardiology, 66: 3A-6A, ( Sep. 4, 1990).
Prediman K. Shah et al., “High-dose Recombinant Apolipoprotein A-I Milano Mobilizes Tissue Cholesterol and Rapidly Reduces Plaque Lipid and Macrophage Content in Apolipoprotein E-Deficient Mice,” Circulation, 103:3047-3050, (Jun. 2001).
Prediman K. Shah et al., “Effects of Recombinant Apolipoprotein A-I Milano on Aortic Atherosclerosis in Apolipoprotein E-Deficient Mice,” Circulation, 97:780-785, (Mar. 1998).
Cesare R. Sirtori et al., “Cardiovascular Status of Carriers of the Apolipoprotein A-I Milano Mutant: The Limone sul Garda Study,” Circulation, 103:1949-1954, (Apr. 2001).
M.G. Sorci-Thomas et al., “Alteration in apolipoprotein A-I 22-mer repeat order results in a decrease in lecithin:cholesterol acyltransferase reactivity,” J. Bio. Chem., 272:7278-7284, (Mar. 14, 1997).
M.G. Sorci-Thomas et al., “The hydrophobic face orientation of apolipoprotein A-I amphipathic helix domain 143-164 regulates lecithin-cholesterol acyltransferase activation,” J. Bio. Chem., 273:11776-11782, (May 8, 1998).
Peter W.F. Wilson, “High-Density Lipoprotein, Low-Density Lipoprotein and Coronary Artery Disease,” Am J Cardiol, 66:7A-10A, ( Sep. 4, 1990).
Karl H. Weisgraber et al., “A-I Milano Apoprotein: Isolation and Characterization of Cysteine-containing Variant of the A-I Apoprotein from Human High Density Lipoproteins,” J. Clin. Invest., 66: 901-907, ( Nov. 13, 1980).
Karl H. Weisgraber, “Apolipoprotein A-I Milano: Detection of Normal A-I in Affected Subjects and Evidence for a Cysteine for Arginine Substitution in the Variant A-I,” J. Biol. Chem., 258, 4:2508-2513, (Feb. 1983).
Innerarity, T.L. et al., “The Receptor-Binding Domain of Human Apolipoprotein E, Binding of Apolipoprotein E Fragments,”The Journal of Biological Chemistry, Oct. 25, 1983, vol. 258, No. 20, pp. 12341-12347.
Innerarity, T.L. et al., “Normalization of Receptor Binding of Apolipoprotein E2, Evidence for Modulation of the Binding Site Conformation,”The Journal of Biological Chemistry, Jun. 10, 1984, vol. 259, No. 11, pp. 7261-7267.
Rall, S.C. Jr. et al., “Human Apolipoprotein E, The Complete Amino Acid Sequence,”The Journal of Biological Chemistry, Apr. 25, 1982, vol. 257, No. 8, pp. 4171-4178.
Weisgraber, K.H. et al., “The Receptor-Binding Domain of Human Apolipoprotein E, Monoclonal Antibody Inhibition of Binding,”The Journal of Biological Chemistry, Oct. 25, 1983, vol. 258, No. 20, pp. 12348-123
Kosar Andrew D
The Regents of the University of California
Townsend and Townsend / and Crew LLP
LandOfFree
Cysteine-containing peptides having antioxidant properties does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cysteine-containing peptides having antioxidant properties, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cysteine-containing peptides having antioxidant properties will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4103324